IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Nanogel-Based Therapeutics for Vitiligo: A Comprehensive Review

Corresponding Author: Zubiya Ammar Momin

Co-authors : 1) Needa Mulani - Student

2) Soha Momin – Student

Allana College of Pharmacy, Department of B' Pharmacy, Savitribai Phule University, Pune, Maharashtra, Pune.

Project Guide Name : Sana Attar(Allana College of Pharmacy)

✨Abstract

Vitiligo is a chronic depigmenting disorder characterized by the selective destruction of melanocytes. Conventional therapies often suffer from poor skin penetration, systemic side effects, and variable efficacy. Nanogel-based drug delivery systems offer a promising alternative by enhancing epidermal targeting, improving bioavailability, and enabling sustained release of therapeutic agents. This review explores the pathophysiology of vitiligo, current treatment limitations, and the emerging role of nanogels—particularly phytochemical-loaded and polymeric nanogels—in vitiligo management.

1. Introduction

Vitiligo is a chronic, idiopathic skin disorder characterized by the progressive loss of functional melanocytes, resulting in depigmented patches on the skin and mucous membranes. Affecting approximately 0.5–2% of the global population, vitiligo poses not only cosmetic concerns but also significant psychological and social burdens due to its visible nature and unpredictable progression. The pathogenesis of vitiligo is multifactorial, involving autoimmune responses, oxidative stress, genetic predisposition, and neural mechanisms. Despite decades of research, a definitive cure remains elusive, and current treatment modalities often yield inconsistent results.

Topical therapies—including corticosteroids, calcineurin inhibitors, and photochemotherapy—are commonly employed for localized vitiligo. However, these approaches are limited by poor skin penetration, frequent relapses, and adverse effects such as skin atrophy and irritation. Moreover, the stratum corneum acts as a formidable barrier to drug delivery, particularly for hydrophobic or labile compounds. This has prompted the exploration of advanced drug delivery systems that can overcome these limitations and offer targeted, sustained, and patient-friendly solutions.

Nanogels—nanoscale hydrogel particles composed of crosslinked polymeric networks—have emerged as a promising platform in dermatological therapeutics. Their unique physicochemical properties, including high water content, tunable size, and responsive behavior to stimuli (e.g., temperature, pH),

make them ideal carriers for topical delivery. Nanogels can encapsulate both hydrophilic and lipophilic drugs, protect sensitive actives from degradation, and facilitate controlled release at the site of action. Importantly, their ability to penetrate the skin and interact with cellular targets such as melanocytes opens new avenues for vitiligo management.

Recent studies have demonstrated the potential of nanogels loaded with antioxidants, immunomodulators, and melanocyte-stimulating agents to restore pigmentation and reduce oxidative damage. Phytochemical-based nanogels, such as those containing Piperine, Resveratrol, and Psoralen, offer synergistic effects by combining anti-inflammatory, antioxidant, and melanogenic properties. Synthetic polymeric systems using Pluronic F127, Carbopol 940, and chitosan further enhance formulation stability, skin retention, and patient compliance.

2. Pathophysiology of Vitiligo

Vitiligo is a multifactorial disorder characterized by the progressive loss of melanocytes from the epidermis and hair follicles, leading to depigmented macules. The underlying mechanisms are complex and interrelated, involving genetic predisposition, immune dysregulation, oxidative stress, and neurochemical imbalances. Understanding these pathways is crucial for designing targeted therapies, including nanogel-based interventions.

2.1 Genetic Susceptibility

Vitiligo has a strong genetic component, with over 30 susceptibility loci identified through genome-wide association studies (GWAS). Key genes implicated include:

- **NLRP1** and **PTPN22**: involved in immune regulation and autoimmunity.
- **TYR** and **OCA2**: associated with melanogenesis and pigment biosynthesis.
- **FOXP3** and **IL2RA**: linked to regulatory T-cell function.

These genetic variants contribute to a predisposition for melanocyte vulnerability and immune-mediated destruction.

2.2 Autoimmune Mechanisms

The most widely accepted hypothesis is that vitiligo is an autoimmune disease targeting melanocytes. Key features include:

- **CD8+ cytotoxic T cells** infiltrating lesional skin and releasing perforin and granzyme B.
- **Th1 cytokine profile**, including elevated IFN-γ, TNF-α, and CXCL10, which perpetuate inflammation and melanocyte apoptosis.
- **Loss of immune tolerance** due to defective regulatory T cells (Tregs), allowing autoreactive responses.

This immune attack leads to melanocyte detachment, apoptosis, and eventual clearance from the epidermis.

2.3 Oxidative Stress

Oxidative stress is both a trigger and amplifier of vitiligo pathogenesis. Melanocytes are particularly sensitive to reactive oxygen species (ROS) due to their high metabolic activity and melanin synthesis. Contributing factors include:

- **Impaired antioxidant defenses**, such as reduced catalase and glutathione peroxidase activity.
- **Accumulation of hydrogen peroxide (H_2O_2)** in lesional skin, which damages cellular proteins, lipids, and DNA.
- **Mitochondrial dysfunction**, leading to increased ROS production and melanocyte apoptosis.

Oxidative stress also promotes antigen presentation and immune activation, linking it to autoimmunity.

2.4 Neurochemical Factors

Neural mechanisms may contribute to segmental vitiligo and stress-induced depigmentation. Proposed pathways include:

- **Catecholamine toxicity**, particularly dopamine and norepinephrine, which can induce oxidative damage.
- **Neuropeptides** such as substance P and α-MSH, which modulate melanocyte activity and immune responses.
- **Sympathetic nerve hyperactivity**, potentially disrupting melanocyte homeostasis.

These factors may explain the asymmetric and dermatomal distribution seen in some vitiligo subtypes.

2.5 Melanocyte Detachment and Apoptosis

Melanocytes in vitiligo lesions show signs of detachment from the basal membrane, possibly due to:

- **Altered expression of adhesion molecules** like E-cadherin and integrins.
- **Inflammatory cytokines** disrupting the extracellular matrix.
- **Anoikis**, a form of apoptosis triggered by loss of cell anchorage.

3. Conventional Treatments and Limitations

Treatment	Mechanism	Limitations
Corticosteroids	Immunosuppression	Skin atrophy, rebound
Calcineurin inhibitors	T-cell modulation	Limited efficacy
Phototherapy (NB-UVB)	Melanocyte stimulation	Time-intensive
Surgical grafting	Cell replacement	Invasive, costly

4. Nanogel Technology: Overview

Nanogels are a class of soft, nanoscale hydrogel particles formed by physically or chemically crosslinked polymer networks. Typically ranging from 20 to 200 nanometers in diameter, these structures combine the high water content and biocompatibility of hydrogels with the size-dependent advantages of nanoparticles. Their unique architecture allows for the encapsulation of both hydrophilic and lipophilic drugs, protection of labile actives, and controlled release at the site of action—making them particularly suited for topical applications in dermatology.

4.1 Structural and Functional Features

Nanogels are composed of polymers such as chitosan, hyaluronic acid, Carbopol, Pluronic F127, and synthetic copolymers like poly(N-isopropylacrylamide). These materials can be tailored to respond to physiological stimuli:

- **Thermoresponsive gels** (e.g., Pluronic F127) undergo sol–gel transitions at skin temperature, enhancing drug retention and absorption.
- **pH-sensitive gels** release drugs in response to local pH changes, useful in inflamed or diseased skin.
- **Mucoadhesive gels** (e.g., chitosan-based) improve residence time and penetration through the stratum corneum.

Their nanoscale size facilitates passive diffusion through skin appendages (hair follicles, sweat glands) and intercellular lipid pathways, bypassing the barrier function of the stratum corneum.

4.2 Advantages Over Conventional Topical Systems

Compared to creams, ointments, and emulsions, nanogels offer several key benefits:

- **Improved skin penetration** due to small particle size and hydration-enhancing properties.
- **Controlled and sustained drug release**, reducing dosing frequency and improving patient compliance.
- **Protection of sensitive actives** (e.g., antioxidants, peptides) from degradation due to light, oxygen, or enzymes.
- **Targeted delivery** to melanocytes or immune cells via surface modification with ligands or antibodies.
- **Minimal greasiness and better cosmetic acceptability**, especially important for facial application in vitiligo.

4.3 Relevance to Vitiligo Therapy

Vitiligo treatment requires precise delivery of actives that can:

- Stimulate melanocyte proliferation and migration
- Suppress autoimmune responses
- Neutralize oxidative stress
- Enhance pigmentation via melanogenesis

Nanogels are uniquely positioned to deliver such multifunctional payloads. For example:

- **Piperine-loaded nanogels** stimulate melanocyte proliferation and migration.
- **Resveratrol and curcumin nanogels** provide potent antioxidant and anti-inflammatory effects.
- **Psoralen nanogels** enhance photochemotherapy outcomes by improving skin retention and reducing systemic absorption.

Moreover, nanogels can be co-loaded with multiple actives, enabling synergistic effects—such as combining immunomodulators with antioxidants or melanogenic agents. Their modular design also allows for customization based on lesion location, skin type, and disease severity.

4.4 Formulation Techniques

Nanogels can be prepared using various methods:

- **Emulsion polymerization**
- **Ionic gelation**
- **Nanoprecipitation**

- **Microfluidic fabrication** (e.g., T-junction or flow-focusing setups)

These techniques allow precise control over particle size, drug loading, and release kinetics. Advanced characterization tools such as dynamic light scattering (DLS), zeta potential analysis, FTIR, and UV-Vis spectroscopy are used to confirm stability, compatibility, and performance.

5. Representative Nanogel Formulation

Ingredient	Function	Quantity
Piperine	Melanocyte stimulant / anti-inflammatory	0.5 g
Resveratrol	Antioxidant / anti-inflammatory	0.5 g
Pluronic F127	Thermoresponsive gel base	20 g
Carbopol 940	Thickening agent	0.5 g
Triethanolamine	pH adjuster	q.s. to pH 6.5–7
Propylene glycol	Co-solvent	10 mL
Ethanol	Co-solvent	10 mL
Distilled Water	Vehicle	q.s. to 100 g

6. Mechanism of Action of Nanogels in Vitiligo Therapy

6.1 Enhanced Skin Penetration

- Nanometric size allows passage through stratum corneum via intercellular and transfollicular routes.
- Hydrophilic polymer matrix facilitates hydration and loosening of tight junctions.

6.2 Targeted Melanocyte Modulation

- Ligand-functionalized nanogels (e.g., hyaluronic acid) bind to CD44 receptors on melanocytes.
- Controlled release of actives like psoralen or tacrolimus modulates immune attack and stimulates melanogenesis.

6.3 Antioxidant and Anti-inflammatory Effects

- Curcumin, resveratrol, and lupeol scavenge reactive oxygen species (ROS), reducing oxidative stress-induced melanocyte apoptosis.
- Downregulation of pro-inflammatory cytokines (e.g., TNF-α, IL-6) restores melanocyte niche.

6.4 Photochemotherapeutic Enhancement

- Psoralen-loaded nanogels improve skin retention and reduce systemic absorption.
- Synergistic effect with NB-UVB or PUVA therapy enhances repigmentation.

6.5 Biocompatibility and Sustained Release

- Natural polymers (chitosan, hyaluronic acid) ensure minimal irritation.
- Crosslinked networks allow prolonged drug release over 12–72 hours, reducing dosing frequency.

7. Conclusion

Nanogels offer a promising advancement in vitiligo treatment by enhancing skin penetration, protecting active ingredients, and enabling sustained release. These nanoscale hydrogels improve therapeutic efficacy of agents like psoralen, tacrolimus, and antioxidants by targeting melanocytes, reducing oxidative stress, and supporting repigmentation. Compared to conventional therapies, nanogels show better skin retention, reduced side effects, and potential for combination with phototherapy. While preclinical results are encouraging, further clinical trials and regulatory clarity are needed to translate these innovations into mainstream dermatological care.

8. References:

1. Upadhyay, V., & Singh, R. (2025). Development and evaluation of topical hyalurosomes nanogel of Calotropis procera for vitiligo. *International Journal of Environmental Sciences*, 11(22s), 440–450. Link
2. Lunawat, A., Katkar, V., Sayyed, G., & Garje, S. (2025). A novel herbal gel for vitiligo treatment: Formulation with Psoralea corylifolia and Cucumis melo extracts. *International Journal of Research Publication and Reviews*, 6(6), 155–163. Link
3. Gugulothu, S., et al. (2023). Formulation and development of nanogel containing green tea extract. *World Journal of Pharmaceutical and Medical Research*, 9(9), 273–285. Link
4. Garg, B. J., et al. (2010). Topical treatment in vitiligo and the potential uses of new drug delivery systems. *Indian Journal of Dermatology, Venereology and Leprology*, 76(3), 231–238.
5. Qadir, A., et al. (2022). Nano-carriers for vitiligo therapy: A compendia review. *Journal of Cosmetic Dermatology*, 21(11), 5386–5404.
6. Jain, A., et al. (2021). Curcumin nanogels for skin disorders. *Drug Delivery and Translational Research*, 11(3), 1123–1134.
7. Khan, N., et al. (2020). Resveratrol-loaded nanogels for vitiligo. *Pharmaceutics*, 12(6), 543.
8. Katare, O. P., et al. (2018). Chitosan nanogels for topical immunomodulators. *Journal of Controlled Release*, 285, 75–85.
9. Sharma, S., et al. (2019). Thermoresponsive nanogels for vitiligo. *International Journal of Pharmaceutics*, 567, 118489.
10. Sun MC, Xu XL, Lou XF, Du YZ. Recent Progress and Future Directions: The Nano-Drug Delivery System for the Treatment of Vitiligo. *Int J Nanomedicine*. Link
11. Lunawat A, Katkar V, Sayyed G, Garje S. A Novel Herbal Gel for Vitiligo Treatment: Formulation with Psoralea Corylifolia and Cucumis Melo Extracts. *Int J Res Publ Rev*. 2025;6(6):155-163. Link
12. Garg BJ, Saraswat A, Bhatia A, Katare OP. Topical treatment in vitiligo and the potential uses of new drug delivery systems. *Indian J Dermatol Venereol Leprol*. 2010;76(3):231-238. Link
13. Katare OP, Vyas SP, Dixit VK. Novel drug delivery systems in topical treatment of vitiligo: liposomes and beyond. *Drug Dev Ind Pharm*. 2007;33(8):861–873.
14. Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes—a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. *Drug Dev Ind Pharm*. 2003;29(9):1013–1026.
15. Rani S, Rana R, Dahiya L. Nanogel-based topical delivery of tacrolimus for vitiligo: formulation and evaluation. *J Drug Deliv Sci Technol*. 2021;61:102263.
16. Bhatia A, Kumar R, Katare OP. Tamoxifen-loaded liposomes for topical application: development, characterization and in vivo evaluation. *J Pharm Pharm Sci*. 2004;7(2):252–258.
17. Jain A, Jain SK. In vitro and in vivo evaluation of liposomes containing oxcarbazepine for dermal delivery. *Drug Dev Ind Pharm*. 2010;36(8):985–994.
18. Sharma A, Garg T, Amanpreet K, Rath G, Goyal AK. Nanogel—an advanced drug delivery tool: current and future. *Artif Cells Nanomed Biotechnol*. 2016;44(1):165–177.
19. Singh B, Sharma R, Garg N, Katare OP. Development and evaluation of topical liposomal gel for the treatment of vitiligo. *Indian J Pharm Sci*. 2012;74(4):326–331.
20. Raza K, Kumar P, Kumar N, Malik R, Sharma G, Kaur M, et al. Topical delivery of aceclofenac: development, characterization, and in vivo evaluation. *J Pharm Sci*. 2013;102(3):1001–1012.
21. Chandel A, Chauhan I, Parashar B. Nanogels as targeted drug delivery system: a review. *J Pharm Sci Res*. 2011;3(7):1404–1414.

22. Sahu A, Bora U, Kasoju N, Goswami P. Synthesis of novel biodegradable and biocompatible amphiphilic copolymer for drug delivery. *Int J Pharm*. 2008;350(1–2):257–265.
23. Kumar R, Katare OP. Lecithin organogels as a potential topical drug delivery system: a review. *AAPS PharmSciTech*. 2005;6(2):E298–E310.
24. Sharma G, Sharma AR, Nam JS, Doss GP, Lee SS, Chakraborty C. Nanogel—an advanced drug delivery tool: current and future. *Artif Cells Nanomed Biotechnol*. 2016;44(1):165–177.
25. Jain A, Jain SK. Novel delivery systems for anti-vitiligo agents: a review. *Drug Deliv Lett*. 2012;2(2):123–132.
26. Kaur IP, Garg A, Singla AK, Aggarwal D. Vesicular systems in ocular drug delivery: an overview. *Int J Pharm*. 2004;269(1):1–14.
27. Raza K, Singh B, Kumar M, Sharma G, Kumar N, Malik R, et al. Topical delivery of aceclofenac: development, characterization, and in vivo evaluation. *J Pharm Sci*. 2013;102(3):1001–1012.
28. Jain S, Jain P, Umamaheshwari RB, Jain NK. Transfersomes—a novel vesicular carrier for enhanced transdermal delivery. *Drug Dev Ind Pharm*. 2003;29(9):1013–1026.
29. Sharma A, Garg T, Amanpreet K, Rath G, Goyal AK. Nanogel—an advanced drug delivery tool: current and future. *Artif Cells Nanomed Biotechnol*. 2016;44(1):165–177.
30. Singh B, Sharma R, Garg N, Katare OP. Development and evaluation of topical liposomal gel for the treatment of vitiligo. *Indian J Pharm Sci*. 2012;74(4):326–331.
31. Bhatia A, Kumar R, Katare OP. Tamoxifen-loaded liposomes for topical application. *J Pharm Pharm Sci*. 2004;7(2):252–258.
32. Jain A, Jain SK. In vitro and in vivo evaluation of liposomes containing oxcarbazepine. *Drug Dev Ind Pharm*. 2010;36(8):985–994.
33. Garg BJ, Saraswat A, Bhatia A, Katare OP. Topical treatment in vitiligo and the potential uses of new drug delivery systems. *Indian J Dermatol Venereol Leprol*. 2010;76(3):231–238.
34. Lunawat A, Katkar V, Sayyed G, Garje S. A Novel Herbal Gel for Vitiligo Treatment. *Int J Res Publ Rev*. 2025;6(6):155–163.
35. Sun MC, Xu XL, Lou XF, Du YZ. Nano-Drug Delivery System for Vitiligo. *Int J Nanomedici*Link.
36. Sun, M.-C., Xu, X.-L., Lou, X.-F., & Du, Y.-Z. (2020). Recent progress and future directions: The nano-drug delivery system for the treatment of vitiligo. *International Journal of Nanomedicine*, *15*, 10375–10388. https://doi.org/10.2147/IJN.S245326
37. Darvishi, M., Chekeni, A. M., Fazelhosseini, M., et al. (2025). Lipid-based nanoparticles: Advancing therapeutic strategies for vitiligo management. *BioImpacts*, *15*(3), 145–158. https://pdfs.semanticscholar.org/00d0/8ea456e590395a288b30de500207735bf572.pdf
38. Parga, A. D., & Ray, B. (2025). Lipid nanocarriers for targeted repigmentation in vitiligo: Advances in melanocyte modulation and topical delivery. *International Journal of Nanotechnology & Nanomedicine*. https://www.researchgate.net/publication/392661246
39. Mancuso, A., Cristiano, M. C., d'Avanzo, N., et al. (2024). Nanomedicine as potential response in vitiligo disorder and social impairment. *NANOBALKAN Conference Abstracts*. https://phantomsfoundation.com/NANOBALKAN/2024/Abstracts/NANOBALKAN2024_Mancuso_Antonia_68.pdf
40. Kuriakose, B. B. (2025). Beyond skin deep: Exploring the complex molecular mechanisms and holistic management strategies of vitiligo. *Springer Dermatology Reviews*. https://link.springer.com/content/pdf/10.1007/s00403-025-04162-6.pdf
41. Sharma, D., Kaushik, A., & Ankagi, A. D. (2025). Vitiligo: An in-depth review of pathogenesis, clinical aspects, and therapeutic advances. *International Journal of Pharmaceutical Sciences*. https://www.ijpsjournal.com/assetsbackoffice/uploads/article/Vitiligo+An+InDepth+Review.pdf
42. Khan, I., Khan, M. K. A., & Almarshad, F. M. (2024). Exploring therapeutic approaches for vitiligo. *Springer Clinical Dermatology*. https://link.springer.com/content/pdf/10.1007/s13671-024-00425-z.pdf
43. Ghosh, S., & Mukhopadhyay, S. (2023). Nanogel-based delivery of corticosteroids for vitiligo: A comparative study. *Journal of Dermatological Science*, *110*(2), 85–92.
44. Patel, R., & Mehta, T. (2022). Advances in nanotechnology for dermatological disorders: Focus on vitiligo. *Nanomedicine Research Journal*, *7*(1), 45–58.
45. Singh, A., & Verma, R. (2021). Polymeric nanogels for topical drug delivery in vitiligo: A review. *International Journal of Pharmaceutical Investigation*, *11*(3), 120–128.
46. Zhang, Y., & Li, H. (2020). Targeted delivery of immunomodulators using nanogels for vitiligo therapy. *Journal of Controlled Release*, *322*, 456–468.

47. Alqahtani, M. S., & Alshahrani, S. M. (2023). Nanocarrier systems for skin disorders: Vitiligo as a model disease. *Saudi Pharmaceutical Journal*, *31*(5), 612–620.
48. Gupta, N., & Sharma, R. (2022). Nanogel-mediated delivery of herbal extracts for vitiligo management. *Phytomedicine Plus*, *2*(4), 100234.
49. Roy, P., & Das, S. (2023). Nanotechnology in autoimmune skin diseases: Emerging trends in vitiligo treatment. *Autoimmunity Reviews*, *22*(1), 102983.
50. El-Sayed, M., & El-Masry, M. (2021). Nanogel-based phototherapy enhancers for vitiligo. *Photodermatology, Photoimmunology & Photomedicine*, *37*(6), 482–490.
51. Choudhury, A., & Banerjee, S. (2022). Role of nanogels in enhancing skin penetration of vitiligo drugs. *Journal of Drug Delivery Science and Technology*, *68*, 103034.
52. Ahmed, T., & Khan, M. (2023). Nanogel formulations for topical immunotherapy in vitiligo. *Journal of Immunological Methods*, *510*, 113432.
53. Ramesh, S., & Kumar, V. (2021). Nanotechnology-based approaches for vitiligo: A systematic review. *Dermatologic Therapy*, *34*(2), e14890.
54. Oliveira, M. C., & Silva, J. (2020). Nanogels for transdermal delivery of antioxidants in vitiligo. *European Journal of Pharmaceutics and Biopharmaceutics*, *152*, 234–242.
55. Bhatia, A., & Thakur, R. (2022). Nanogel-based delivery of JAK inhibitors for vitiligo treatment. *Drug Development and Industrial Pharmacy*, *48*(9), 1456–1464.